Literature DB >> 29035367

Targeting glioma stem cells through combined BMI1 and EZH2 inhibition.

Xun Jin1,2,3, Leo J Y Kim1,4,5,6, Qiulian Wu1,6, Lisa C Wallace1, Briana C Prager1,4,5,6,7, Tanwarat Sanvoranart1, Ryan C Gimple1,4,5,6, Xiuxing Wang1,6, Stephen C Mack1,8, Tyler E Miller1,4,5, Ping Huang1, Claudia L Valentim1, Qi-Gang Zhou1, Jill S Barnholtz-Sloan9, Shideng Bao1,7,9, Andrew E Sloan9,10, Jeremy N Rich1,6,7,9.   

Abstract

Glioblastomas are lethal cancers defined by angiogenesis and pseudopalisading necrosis. Here, we demonstrate that these histological features are associated with distinct transcriptional programs, with vascular regions showing a proneural profile, and hypoxic regions showing a mesenchymal pattern. As these regions harbor glioma stem cells (GSCs), we investigated the epigenetic regulation of these two niches. Proneural, perivascular GSCs activated EZH2, whereas mesenchymal GSCs in hypoxic regions expressed BMI1 protein, which promoted cellular survival under stress due to downregulation of the E3 ligase RNF144A. Using both genetic and pharmacologic inhibition, we found that proneural GSCs are preferentially sensitive to EZH2 disruption, whereas mesenchymal GSCs are more sensitive to BMI1 inhibition. Given that glioblastomas contain both proneural and mesenchymal GSCs, combined EZH2 and BMI1 targeting proved more effective than either agent alone both in culture and in vivo, suggesting that strategies that simultaneously target multiple epigenetic regulators within glioblastomas may be effective in overcoming therapy resistance caused by intratumoral heterogeneity.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29035367      PMCID: PMC5679732          DOI: 10.1038/nm.4415

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  60 in total

1.  Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma.

Authors:  Tian-Yu Fan; Hai Wang; Peng Xiang; Ya-Wei Liu; He-Zhen Li; Bing-Xi Lei; Meng Yu; Song-Tao Qi
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

2.  ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors.

Authors:  Ping Zhang; Mark C de Gooijer; Levi C M Buil; Jos H Beijnen; Gang Li; Olaf van Tellingen
Journal:  Int J Cancer       Date:  2015-04-24       Impact factor: 7.396

3.  BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery.

Authors:  Sabrina Facchino; Mohamed Abdouh; Wassim Chatoo; Gilbert Bernier
Journal:  J Neurosci       Date:  2010-07-28       Impact factor: 6.167

4.  EZH2 is essential for glioblastoma cancer stem cell maintenance.

Authors:  Mario-Luca Suvà; Nicolò Riggi; Michalina Janiszewska; Ivan Radovanovic; Paolo Provero; Jean-Christophe Stehle; Karine Baumer; Marie-Aude Le Bitoux; Denis Marino; Luisa Cironi; Victor E Marquez; Virginie Clément; Ivan Stamenkovic
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

5.  In vivo RNAi screen for BMI1 targets identifies TGF-β/BMP-ER stress pathways as key regulators of neural- and malignant glioma-stem cell homeostasis.

Authors:  Gaetano Gargiulo; Matteo Cesaroni; Michela Serresi; Nienke de Vries; Danielle Hulsman; Sophia W Bruggeman; Cesare Lancini; Maarten van Lohuizen
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

6.  Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.

Authors:  Zhizhong Li; Shideng Bao; Qiulian Wu; Hui Wang; Christine Eyler; Sith Sathornsumetee; Qing Shi; Yiting Cao; Justin Lathia; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

7.  An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Authors:  Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff
Journal:  Science       Date:  2013-04-04       Impact factor: 47.728

8.  Vascular progenitors from cord blood-derived induced pluripotent stem cells possess augmented capacity for regenerating ischemic retinal vasculature.

Authors:  Tea Soon Park; Imran Bhutto; Ludovic Zimmerlin; Jeffrey S Huo; Pratik Nagaria; Diana Miller; Abdul Jalil Rufaihah; Connie Talbot; Jack Aguilar; Rhonda Grebe; Carol Merges; Renee Reijo-Pera; Ricardo A Feldman; Feyruz Rassool; John Cooke; Gerard Lutty; Elias T Zambidis
Journal:  Circulation       Date:  2013-10-25       Impact factor: 29.690

9.  RNF144A, an E3 ubiquitin ligase for DNA-PKcs, promotes apoptosis during DNA damage.

Authors:  Shiuh-Rong Ho; Christina S Mahanic; Yu-Ju Lee; Weei-Chin Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-16       Impact factor: 11.205

10.  RYBP-PRC1 complexes mediate H2A ubiquitylation at polycomb target sites independently of PRC2 and H3K27me3.

Authors:  Lígia Tavares; Emilia Dimitrova; David Oxley; Judith Webster; Raymond Poot; Jeroen Demmers; Karel Bezstarosti; Stephen Taylor; Hiroki Ura; Hiroshi Koide; Anton Wutz; Miguel Vidal; Sarah Elderkin; Neil Brockdorff
Journal:  Cell       Date:  2012-02-09       Impact factor: 41.582

View more
  128 in total

1.  N6-methyladenine DNA Modification in Glioblastoma.

Authors:  Qi Xie; Tao P Wu; Ryan C Gimple; Zheng Li; Briana C Prager; Qiulian Wu; Yang Yu; Pengcheng Wang; Yinsheng Wang; David U Gorkin; Cheng Zhang; Alexis V Dowiak; Kaixuan Lin; Chun Zeng; Yinghui Sui; Leo J Y Kim; Tyler E Miller; Li Jiang; Christine H Lee; Zhi Huang; Xiaoguang Fang; Kui Zhai; Stephen C Mack; Maike Sander; Shideng Bao; Amber E Kerstetter-Fogle; Andrew E Sloan; Andrew Z Xiao; Jeremy N Rich
Journal:  Cell       Date:  2018-11-01       Impact factor: 41.582

2.  Targeting of BMI-1 with PTC-209 inhibits glioblastoma development.

Authors:  Yu Kong; Chunbo Ai; Feng Dong; Xianyou Xia; Xiujuan Zhao; Chao Yang; Chunsheng Kang; Yan Zhou; Qian Zhao; Xiujing Sun; Xudong Wu
Journal:  Cell Cycle       Date:  2018-07-23       Impact factor: 4.534

3.  Off-target effect of the BMI1 inhibitor PTC596 drives epithelial-mesenchymal transition in glioblastoma multiforme.

Authors:  Anthony Flamier; Mohamed Abdouh; Rimi Hamam; Andrea Barabino; Niraj Patel; Andy Gao; Roy Hanna; Gilbert Bernier
Journal:  NPJ Precis Oncol       Date:  2020-01-06

4.  Paracaspase MALT1 regulates glioma cell survival by controlling endo-lysosome homeostasis.

Authors:  Kathryn A Jacobs; Gwennan André-Grégoire; Clément Maghe; An Thys; Ying Li; Elizabeth Harford-Wright; Kilian Trillet; Tiphaine Douanne; Carolina Alves Nicolau; Jean-Sébastien Frénel; Nicolas Bidère; Julie Gavard
Journal:  EMBO J       Date:  2019-11-27       Impact factor: 11.598

5.  Chromatin remodeler HELLS maintains glioma stem cells through E2F3 and MYC.

Authors:  Guoxin Zhang; Zhen Dong; Briana C Prager; Leo Jk Kim; Qiulian Wu; Ryan C Gimple; Xiuxing Wang; Shideng Bao; Petra Hamerlik; Jeremy N Rich
Journal:  JCI Insight       Date:  2019-04-04

6.  Modeling Gliomas Using Two Recombinases.

Authors:  Toshiro Hara; Inder M Verma
Journal:  Cancer Res       Date:  2019-07-17       Impact factor: 12.701

Review 7.  Cancer Stem Cells: The Architects of the Tumor Ecosystem.

Authors:  Briana C Prager; Qi Xie; Shideng Bao; Jeremy N Rich
Journal:  Cell Stem Cell       Date:  2019-01-03       Impact factor: 24.633

8.  Treatment of glioblastoma using multicomponent silica nanoparticles.

Authors:  O Turan; P A Bielecki; V Perera; M Lorkowski; G Covarrubias; K Tong; A Yun; Georgia Loutrianakis; S Raghunathan; Y Park; T Moon; S Cooley; D Dixit; M A Griswold; K B Ghaghada; P M Peiris; J N Rich; E Karathanasis
Journal:  Adv Ther (Weinh)       Date:  2019-09-04

Review 9.  Targeting epigenetics using synthetic lethality in precision medicine.

Authors:  Ee Sin Chen
Journal:  Cell Mol Life Sci       Date:  2018-07-12       Impact factor: 9.261

10.  Intratumoral spatial heterogeneity of BTK kinomic activity dictates distinct therapeutic response within a single glioblastoma tumor.

Authors:  Ahmed N Ibrahim; Daisuke Yamashita; Joshua C Anderson; Moaaz Abdelrashid; Amr Alwakeal; Dagoberto Estevez-Ordonez; Svetlana Komarova; James M Markert; Violaine Goidts; Christopher D Willey; Ichiro Nakano
Journal:  J Neurosurg       Date:  2019-10-18       Impact factor: 5.115

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.